Citadel Advisors’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Citadel Advisors’s Portfolio HARP Stock Details HARP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,210	Closed	-$8.59K	–	15501
2023 Q2	$8.59K	Sell	1,210 -110	-8%	-$761	﹤0.01%	13311
2023 Q1	$9.82K	Buy	1,320 +450	+52%	+$3.78K	﹤0.01%	13560
2022 Q4	$6.31K	Buy	+870	New	+$7.33K	﹤0.01%	13928
2022 Q2	–	Sell	-1,110	Closed	-$55K	–	14544
2022 Q1	$55K	Sell	1,110 -1,740	-61%	-$90.2K	﹤0.01%	12737
2021 Q4	$215K	Buy	2,850 +70	+3%	+$4.78K	﹤0.01%	11702
2021 Q3	$220K	Sell	2,780 -2,060	-43%	-$207K	﹤0.01%	11793
2021 Q2	$671K	Sell	4,840 -2,720	-36%	-$519K	﹤0.01%	9346
2021 Q1	$1.58M	Buy	7,560 +2,330	+45%	+$467K	﹤0.01%	6975
2020 Q4	$869K	Buy	+5,230	New	+$808K	﹤0.01%	7084

Citadel Advisors's HARP Position: Q1 2024 in Review

Citadel Advisors sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 685,000 shares — an estimated $7.79M sold.

Citadel Advisors first reported a position in HARP in Q2 2020 and held it in 12 quarters. The position peaked at $7.79M in Q4 2023. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.

Citadel Advisors reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 685,000 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $7.79M.
Citadel Advisors first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
Citadel Advisors's Harpoon Therapeutics, Inc. Common Stock position peaked at $7.79M in Q4 2023.
0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.